Abbott reports positive results from study on its atrial fibrillation therapies

Abbott (NYSE: ABT) on Friday reported positive data from studies evaluating the safety and effectiveness of its Volt Pulsed Field Ablation system for treating drug-refractory paroxysmal and persistent atrial fibrillation. The report, presented at the AF Symposium and simultaneously published in JACC: Clinical Electrophysiology, reinforces the Volt PFA System’s success rate for treating atrial fibrillation.

The results include 12-month findings that confirm the long-term safety and performance of the Volt PFA System. Volt also delivered strong results as a treatment option for AFib episodes that last longer than seven days, with nearly 68% of patients remaining free from additional episodes. It was found in the study that less than 6% of patients required a repeat ablation, one of the lowest rates in the industry. Last year, the Volt PFA System secured US Food and Drug Administration approval and CE Mark in Europe.